Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

Completed

Phase 3 Results

Summary of Purpose

The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 3 September 2015.

1 Mar 2008 17 Apr 2008 1 Sep 2009 1 Sep 2009 1 Sep 2015 5 Sep 2014
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Crossover Assignment

Contacts

Not available